Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roxanne Cofiell

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Advances in Therapy|July 5, 2022
The Role of Complement in HSCT-TMA: Basic Science to Clinical PracticeSeppo Meri, Donald Bunjes, Roxanne Cofiell, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 8, 2008
Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapyAnke Kretz-Rommel, Fenghua Qin, Naveen Dakappagari, et al.
Blood|April 3, 2015
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUSRoxanne Cofiell, Anjli Kukreja, Krystin Bedard, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Advances in Therapy|July 5, 2022
The Role of Complement in HSCT-TMA: Basic Science to Clinical PracticeSeppo Meri, Donald Bunjes, Roxanne Cofiell, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 8, 2008
Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapyAnke Kretz-Rommel, Fenghua Qin, Naveen Dakappagari, et al.
Blood|April 3, 2015
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUSRoxanne Cofiell, Anjli Kukreja, Krystin Bedard, et al.
Pageof 1